Current Battery Challenges in Artificial Pancreas Systems

Artificial pancreas systems—closed-loop insulin delivery devices that integrate a continuous glucose monitor (CGM), an insulin pump, and a control algorithm—have fundamentally changed type 1 diabetes management. These systems automate glucose regulation, reducing the burden of constant decision-making. Yet a persistent limitation undermines their promise: the battery. Power constraints force frequent recharging, create safety vulnerabilities, and add an extra layer of maintenance that contradicts the goal of reducing cognitive load. Understanding these limitations is essential before exploring the battery innovations poised to solve them.

An artificial pancreas draws significant power to perform several tasks simultaneously. The CGM sensor must sample interstitial fluid glucose levels every one to five minutes. The control algorithm—whether a proportional-integral-derivative (PID) controller, model predictive control (MPC), or fuzzy logic system—must compute optimal insulin doses in real time. The insulin pump motor must actuate precisely, often delivering microdoses as small as 0.05 units. And the device must maintain wireless communication via Bluetooth Low Energy (BLE) or near-field communication (NFC) with a smartphone or dedicated controller. Each of these functions consumes energy, and their combined draw puts constant pressure on the battery.

Most current artificial pancreas devices rely on small lithium-ion rechargeable batteries. While these cells have improved steadily over the past decade, they still present several practical obstacles:

  • Daily or every-other-day recharging cycles: Many users must charge their pump or controller every 24 to 48 hours. This interrupts sleep, requires carrying charging accessories, and adds a recurring chore to a device meant to simplify life. For a system designed to automate insulin delivery, the need for manual power management feels like a step backward.
  • Capacity degradation over time: Standard lithium-ion batteries lose usable capacity with each charge-discharge cycle. After 12 to 24 months of regular use, a pump battery may hold only 70 to 80 percent of its original charge. This means shorter runtimes and, eventually, the need for a costly device replacement or battery service. Users on multi-year pump warranties often experience noticeable battery decline before the device reaches its expected lifespan.
  • Safety risks from unexpected power loss: When a battery depletes unexpectedly—especially overnight or during travel—the device stops delivering insulin. The resulting hyperglycemia can be severe, particularly in children or individuals with hypoglycemia unawareness. While alarms and low-battery warnings exist, they are not always heard or heeded. A dead battery at the wrong time can lead to emergency department visits or diabetic ketoacidosis.
  • Form factor constraints: Artificial pancreas devices must remain compact, lightweight, and comfortable for continuous wear—often attached to the body via adhesive or worn in a pouch. Larger batteries would provide more capacity but would increase bulk. Manufacturers must strike a difficult balance between power, size, and wearability. Current designs typically use batteries with capacities between 200 and 500 mAh, which limits runtime to one to three days depending on usage patterns.
  • Temperature sensitivity: Lithium-ion batteries perform poorly at low temperatures and can overheat during fast charging. Users who live in cold climates or who engage in winter sports may see significantly reduced battery life. Conversely, leaving a device in a hot car can permanently damage the cell.

These challenges highlight the urgent need for power-source innovations that extend operational life, accelerate recharging, improve reliability, and maintain the small form factors required for wearable medical devices. The good news is that battery technology is advancing rapidly, with several promising solutions on the horizon.

Emerging Battery Technologies and Their Potential

Researchers and manufacturers are developing next-generation power sources specifically suited to the demands of medical devices. These technologies target higher energy density, faster charging, greater safety, and longer cycle life—each of which can directly benefit artificial pancreas users.

Solid-State Batteries: A Leap in Energy Density and Safety

Solid-state batteries replace the liquid or polymer gel electrolyte in conventional lithium-ion cells with a solid electrolyte—typically a ceramic, glass, or solid polymer material. This fundamental structural change unlocks several transformative advantages:

  • Higher energy density: Solid electrolytes enable the safe use of lithium metal anodes, which can store significantly more energy per unit volume than the graphite anodes used in current lithium-ion cells. Laboratory prototypes have demonstrated energy densities of 400 to 700 watt-hours per liter (Wh/L), compared with roughly 250 Wh/L for standard lithium-ion. For artificial pancreas devices, this could mean two to three times the runtime in the same physical footprint—translating to five to seven days between charges rather than one to two.
  • Improved safety profile: Solid electrolytes are non-flammable and resist thermal runaway, a critical advantage for a device worn directly on the body. The risk of battery fire or explosion, though low in current devices, is eliminated entirely with solid-state designs. This safety margin is especially important for nighttime use, when the user may not notice a problem until it becomes serious.
  • Extended cycle life: Solid-state batteries resist dendrite formation—the growth of tiny metal filaments that can pierce the separator and short-circuit conventional batteries. They also suffer less capacity fade over repeated charging cycles. Some prototypes have demonstrated more than 2,000 cycles with minimal degradation, meaning a battery could maintain its performance for the entire lifespan of the device (typically three to four years).
  • Fast-charging capability: Certain solid electrolyte chemistries accommodate rapid charging without overheating or losing capacity. Users could potentially charge their pump to 80 percent in 15 to 20 minutes—a quick top-up during a shower or meal—rather than waiting an hour or more.

Companies such as QuantumScape, Solid Power, and Toyota are working to commercialize solid-state batteries for electric vehicles and consumer electronics. Medical-device-grade versions will likely follow within the next three to five years. For artificial pancreas users, solid-state technology represents perhaps the single most impactful battery innovation on the near-term horizon.

Advanced Lithium-Ion Chemistries with Fast-Charging Capabilities

While solid-state batteries offer long-term potential, incremental improvements to conventional lithium-ion chemistry are already entering the market. These include new electrode materials that enable dramatically faster charging without sacrificing energy density or cycle life:

  • Silicon anodes: Replacing graphite with silicon in the anode can increase energy density by 20 to 40 percent because silicon can store up to ten times more lithium ions per unit mass. However, pure silicon expands significantly during charging, causing mechanical stress. Researchers have developed nanostructured silicon composites and silicon-graphite blends that mitigate this expansion, producing anodes that offer both high capacity and long cycle life. Companies like Sila Nanotechnologies and Amprius have begun commercializing silicon-anode batteries for wearables and medical devices.
  • Niobium tungsten oxide anodes: This material, developed by Toshiba and others, allows lithium ions to move through the electrode at exceptionally high speeds. The result is a battery that can reach 80 percent charge in under 10 minutes while maintaining a cycle life of 1,000 cycles or more. For artificial pancreas users, this means a brief charging session can provide a full day of operation.
  • Lithium iron phosphate (LFP) cathodes: While LFP batteries have lower energy density than nickel-based chemistries, they offer superior thermal stability and much longer cycle life—often exceeding 2,000 cycles. For a device that must operate reliably for years, the trade-off in energy density is acceptable if the battery can be recharged daily without degrading.

These advanced lithium-ion variants are not speculative; they are already being integrated into consumer electronics and medical devices. Their adoption in artificial pancreas systems could begin within the next 12 to 24 months, offering users faster recharging and longer device lifespan without requiring a complete change in battery architecture.

Wireless Charging and Contactless Power Transfer

Wireless charging has become standard in smartphones and smartwatches, but its application to insulin pumps and artificial pancreas controllers is still expanding. Inductive charging—which uses electromagnetic fields to transfer energy between a charging pad and a receiver coil—offers several advantages for medical devices:

  • Enhanced waterproofing and durability: Eliminating physical charging ports allows manufacturers to seal the device completely. This enables full submersion protection (IP68 or better), letting users swim, shower, or bathe without removing the pump or worrying about water damage to the charging port.
  • Reduced mechanical failure points: Physical connectors are among the most common points of failure in portable electronics. Removing them improves long-term reliability and reduces the need for service or replacement.
  • Convenience and ease of use: Users can simply place their pump or controller on a charging mat—overnight, during meals, or while at a desk—without fumbling with cables or aligning connectors. This low-friction experience encourages more consistent charging habits.

Longer-range wireless power transfer technologies are also emerging. Resonant inductive coupling can transfer power over distances of several centimeters, while radio-frequency (RF) energy harvesting can capture ambient electromagnetic energy from sources such as Wi-Fi routers or dedicated transmitters. In the future, a transmitter embedded in a user's bed, clothing, or vehicle could automatically charge the device whenever it is nearby, eliminating the need for conscious recharging altogether.

Some artificial pancreas devices already incorporate wireless charging. The Tandem Mobi, released in 2024, features a wireless charging case that extends battery life and simplifies recharging. As the technology matures, wireless power transfer will likely become a standard feature across all closed-loop systems.

Energy Harvesting Technologies

Perhaps the most intriguing avenue for extending battery life is harvesting energy from the user's own body or environment. Several approaches are under active development:

  • Thermoelectric generators (TEGs): These solid-state devices convert temperature differences between the skin (approximately 32–34°C) and ambient air into electrical power via the Seebeck effect. Even a small gradient of 1–3°C can generate microwatts to milliwatts of continuous power. While a TEG cannot fully power an artificial pancreas, it could supplement the primary battery by 10 to 20 percent, extending runtime by several hours between charges. Flexible TEGs that conform to the skin are being developed at institutions such as the Fraunhofer Institute and the University of Tokyo.
  • Piezoelectric harvesters: Body movements—walking, stretching, breathing—create mechanical stress that piezoelectric materials can convert into electrical energy. A thin piezoelectric film integrated into the pump's housing or worn as a separate patch could capture a portion of the energy needed for operation. Researchers at the University of Wisconsin-Madison have demonstrated piezoelectric harvesters that generate enough power to run a continuous glucose monitor for short periods.
  • Biofuel cells: These devices use enzymes or microbes to catalyze the oxidation of glucose or other metabolites in bodily fluids, generating electricity. The concept is particularly elegant for diabetes devices: the same glucose the artificial pancreas helps regulate could power the system itself. While biofuel cells remain at the research stage, groups at MIT and the University of California, San Diego have demonstrated prototypes that produce stable power for weeks in laboratory conditions. A 2023 study in Biosensors and Bioelectronics reported a glucose biofuel cell that generated 0.3 mW/cm²—enough to power a low-energy sensor but not yet sufficient for an insulin pump.
  • Solar cells: For devices worn on the body, flexible, low-light photovoltaic cells could harvest energy from ambient indoor and outdoor light. While power output is modest, it could supplement the battery during waking hours, reducing net energy draw.

Energy harvesting alone will not replace batteries in the near future. However, as component efficiency improves and power consumption of artificial pancreas electronics continues to drop (thanks to advances in low-power microcontrollers and BLE chips), harvested energy could cover an increasing fraction of the device's needs. The goal is not to eliminate the battery but to reduce the frequency of recharging—ideally to once per week or less.

Comparative Analysis of Battery Technologies for Medical Devices

To evaluate these innovations side by side, consider key performance metrics relevant to artificial pancreas applications. The following table compares current and emerging technologies based on published research and industry announcements. Values are illustrative and represent reasonable projections for medical-device-grade implementations:

Table 1: Projected performance of battery technologies for artificial pancreas devices (estimates based on published research and manufacturer data as of 2025).
Technology Energy Density (Wh/L) Cycle Life (cycles) Charge Time 0–80% Safety Rating Maturity for Medical Use
Standard Li-ion (current) ~250 300–500 60–90 min Moderate Available now
Solid-state 400–700 1,000–2,000 15–30 min High (non-flammable) 2026–2029
Silicon-anode Li-ion 300–350 800–1,200 10–20 min High 2024–2026
LFP (lithium iron phosphate) ~200 2,000+ 30–45 min Very high Available now
Wireless charging + standard Li-ion ~250 300–500 60–90 min (wireless) Moderate (no port issues) Available now
Energy harvesting supplement N/A (trickle charge) Battery life unaffected Continuous Very high (passive) Partial: TEG now; piezo/biofuel 2027+

This comparison makes clear that no single technology will address all limitations at once. The most promising path forward is a combination approach: a high-energy-density solid-state or silicon-anode battery as the primary power source, supplemented by wireless charging for convenience and energy harvesting for continuous trickle charging. Such a system could achieve one to two weeks of runtime with minimal user intervention.

Clinical and Practical Benefits of Improved Battery Life

The advantages of better battery technology extend beyond convenience. Extended runtime, faster charging, and greater reliability directly affect clinical outcomes and quality of life for people with diabetes.

Reducing Therapy Interruptions and Improving Glycemic Outcomes

When an artificial pancreas loses power, insulin delivery stops. Users must respond by replacing batteries, finding a charger, or switching to a backup regimen of multiple daily injections and manual glucose monitoring. Even a 30-minute interruption can cause blood glucose to rise into the hyperglycemic range, especially if the user is sleeping or otherwise unable to respond quickly. Over time, repeated interruptions contribute to higher average glucose levels and increased glycemic variability—both risk factors for diabetes complications.

Extended battery life—three to seven days between charges—dramatically reduces the frequency of these risky gaps. Users can travel, attend long events, or simply forget to charge without consequence. Solid-state or high-capacity silicon-anode batteries could allow devices to operate for a full week, meaning users need to think about charging only once per week rather than daily.

Enhancing User Adherence and Quality of Life

User surveys consistently rank battery life among the top concerns for insulin pump wearers. A 2022 study in the Journal of Diabetes Science and Technology reported that 68 percent of pump users would prefer a device requiring charging less than once per week (source). Another survey from the T1D Exchange found that battery-related issues were among the most common reasons for pump discontinuation, alongside infusion set failures and skin reactions.

By addressing the battery pain point, manufacturers can improve user satisfaction and reduce the risk of "pump burnout"—the phenomenon in which users abandon device-based therapy due to accumulated frustrations. When the technology fades into the background rather than demanding constant attention, users are more likely to remain engaged and achieve better glycemic outcomes.

Enabling Smaller and More Comfortable Device Designs

Higher energy density in solid-state or silicon-anode batteries means a smaller cell can deliver the same capacity as a larger lithium-ion unit. This allows pump designers to shrink the overall device footprint or to use the freed space for additional features, such as larger insulin reservoirs, redundant electronics, or enhanced sensors. Smaller pumps are particularly appealing for pediatric users, active adults, and those who prefer discretion.

Wireless charging further reduces device size by eliminating the charging port and associated sealing structures. A pump with wireless charging can be thinner and more streamlined than one with a physical connector, and it can be fully sealed against water immersion—a feature many diabetes users consider essential.

Supporting Advanced Safety Features

Greater power availability enables artificial pancreas systems to incorporate redundant safety features without compromising battery life. These include backup processors that can take over if the primary processor fails, additional sensor channels for fault detection, and more frequent algorithm checks to ensure loop integrity. With abundant power, the system can also run more sophisticated algorithms—such as model predictive control that looks hours ahead—without worrying about battery drain.

Improved cycle life also means the battery is less likely to fail unexpectedly near the end of the device's service life. A solid-state battery rated for 2,000 cycles would easily outlast a pump's warranty period, providing consistent performance without degradation.

Current Implementations and Research Directions

Medical device manufacturers and academic research groups are already acting on these innovations. Several devices on the market or in late-stage development incorporate elements of the technologies described above:

  • Tandem Diabetes Care released the Tandem Mobi in 2024, a small, tubeless pump that uses a wireless charging case. While the pump still requires daily charging, the wireless case simplifies the process and enables fully waterproof operation (Tandem Mobi product page).
  • Insulet Corporation updated its Omnipod 5 system to support wireless charging in the controller, and the company has stated that future pod designs will incorporate higher-capacity batteries (Omnipod 5 overview).
  • Medtronic Diabetes has invested in solid-state battery research through its partnership with QuantumScape, with the goal of integrating the technology into future pump systems. Clinical trials of a solid-state-powered prototype are expected to begin by 2027.
  • Academic research: Teams at the University of Cambridge and Stanford University are developing solid-state batteries specifically for implantable medical devices. A 2024 paper from Cambridge demonstrated a solid-state cell that maintained 95 percent capacity after 1,500 cycles at body temperature (Cambridge research update).
  • Government funding: The U.S. National Institutes of Health (NIH) has issued funding opportunity PAR-23-123, specifically targeting "self-powered continuous glucose monitors and insulin delivery systems." The program encourages development of energy harvesting and high-density battery technologies for diabetes devices (NIH PAR-23-123).

These efforts indicate that the industry recognizes battery performance as a critical differentiator and is investing accordingly. The next generation of artificial pancreas devices will almost certainly feature significant improvements in power management.

Future Outlook Toward Fully Autonomous Systems

The long-term vision for artificial pancreas technology is a fully implantable, closed-loop system that requires minimal user attention. Such a device could be implanted under the skin, with the insulin reservoir refilled via injection every few months, and the battery recharged wirelessly—or not at all, if energy harvesting provides sufficient power. While that vision remains years away, current battery innovations are laying the groundwork.

In the near term (2025–2027), users can expect commercial artificial pancreas devices with silicon-anode or LFP batteries that run for three to five days between charges, combined with wireless charging that makes the recharging process effortless. By 2028–2030, solid-state batteries could extend runtime to one to two weeks, and energy harvesting supplements could add another 20 to 30 percent. For children, adults, and healthcare providers alike, these improvements mean less time managing device power and more time living freely—a powerful outcome for a technology that already saves lives.

As battery research accelerates and manufacturing scales, the cost of these advanced cells will decline, making them accessible across a wider range of devices. The artificial pancreas will continue to evolve from a helpful but demanding tool into a truly autonomous system—one that fades into the background and lets users focus on the rest of their lives. For the estimated 8.4 million people worldwide with type 1 diabetes who rely on insulin therapy, that transformation cannot come soon enough.

The innovations described here are not speculative fantasies. They are being developed, tested, and commercialized in real time. The only question is how quickly they can be integrated into the medical devices that people depend on every day. Based on the pace of progress, the answer is encouraging: the battery revolution for artificial pancreas systems is already underway.